Journal of the American Academy of Dermatology, Volume 89, Issue 3 September 2023
Dirk M. Elston, MD
In this month’s JAAD, 2 CME articles address melanoma in skin of color. Blauvelt et al (page 478) examine the efficacy and safety of switching from dupilumab to upadacitinib vs continuous upadacitinib in moderate-to-severe atopic dermatitis. In this open-label extension of a phase 3, randomized, controlled trial, they report that clinical responses were maintained with continuous upadacitinib through 40 weeks and patients experienced good outcomes regardless of prior dupilumab response. No new safety risks were observed. Also in this issue, Strober et al (page 486) report the 2-year interim results from an open-label extension phase 3b trial of bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis. High PASI100 responses achieved with bimekizumab >48 weeks were sustained through week 96. Patients with secukinumab who switched to bimekizumab achieved similar responses.